Addressing These Five Factors Will Empower Your HS Patients to Seek Treatment
With the recent U.S. Food and Drug Administration approval of secukinumab (Cosentyx, Novartis) and a full pipeline, hidradenitis suppurativa (HS) is having a moment. Up until now, the TNF blocker adalimumab was the only approved treatment for moderate to severe HS in people 12 years and older. Now that there are more HS treatment options, Nicole Salame, MD, and […]